CX 159X
Alternative Names: CX-159XLatest Information Update: 04 Apr 2023
Price :
$50 *
At a glance
- Originator CarthroniX
- Class Antifibrotics; Antineoplastics; Antirheumatics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer; Idiopathic pulmonary fibrosis; Osteoarthritis
Most Recent Events
- 15 Mar 2023 CarthroniX plans a phase I/IIa trial for osteoarthritis in the US (CarthroniX pipeline, March 2023)
- 15 Mar 2023 Preclinical trials in Cancer in USA (PO)(CarthroniX pipeline, March 2023)
- 15 Mar 2023 Preclinical trials in Idiopathic pulmonary fibrosis in USA (PO) (CarthroniX pipeline, March 2023)